These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20812358)

  • 1. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity.
    Núñez M
    Hepatology; 2010 Sep; 52(3):1143-55. PubMed ID: 20812358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management.
    Núñez M
    J Hepatol; 2006; 44(1 Suppl):S132-9. PubMed ID: 16364487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
    Labarga P; Soriano V; Vispo ME; Pinilla J; Martin-Carbonero L; Castellares C; Casado R; Maida I; Garcia-Gasco P; Barreiro P
    J Infect Dis; 2007 Sep; 196(5):670-6. PubMed ID: 17674307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver toxicity of antiretroviral drugs.
    Jones M; Núñez M
    Semin Liver Dis; 2012 May; 32(2):167-76. PubMed ID: 22760656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noncirrhotic portal hypertension in HIV infection.
    Vispo E; Morello J; Rodriguez-Novoa S; Soriano V
    Curr Opin Infect Dis; 2011 Feb; 24(1):12-8. PubMed ID: 21157331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Period of onset and lack of clinical manifestation of hepatotoxicity after commencing highly active antiretroviral therapy.
    Ugiagbe RA; Ugiagbe EE
    Niger J Clin Pract; 2012; 15(1):63-7. PubMed ID: 22437093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy.
    Pineda JA; Macías J
    J Antimicrob Chemother; 2005 Apr; 55(4):417-9. PubMed ID: 15731202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steatohepatitis due to antiretroviral therapy.
    Gayle F; Lee MG; Hanchard B; Mills M
    West Indian Med J; 2008 Jan; 57(1):66-9. PubMed ID: 19565942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatotoxicity of antiretroviral therapy.
    Kontorinis N; Dieterich D
    AIDS Rev; 2003; 5(1):36-43. PubMed ID: 12875106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of hepatotoxicity of highly active antiretroviral therapy in a tertiary health centre in Nigeria.
    Ugiagbe RA; Malu AO; Bojuwoye BJ; Onunu AN
    Niger Postgrad Med J; 2012 Sep; 19(3):127-32. PubMed ID: 23064166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.
    Qurishi N; Kreuzberg C; Lüchters G; Effenberger W; Kupfer B; Sauerbruch T; Rockstroh JK; Spengler U
    Lancet; 2003 Nov; 362(9397):1708-13. PubMed ID: 14643119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HAART and the liver: friend or foe?
    Pineda JA; Macías J; Mira JA; Merchante N; del Valle J; Neukam KI
    Eur J Med Res; 2010 Mar; 15(3):93-6. PubMed ID: 20452892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral therapy-related hepatotoxicity: predictors and clinical management.
    Dore G
    J HIV Ther; 2003 Nov; 8(4):96-100. PubMed ID: 14671507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management.
    Jones M; Núñez M
    Curr Opin HIV AIDS; 2011 Nov; 6(6):546-52. PubMed ID: 22001896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HAART and pregnancy. Nelfinavir superiority in hepatotoxicity].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():45. PubMed ID: 15373048
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute liver enzyme elevations in HIV-1-infected patients.
    Livry C; Binquet C; Sgro C; Froidure M; Duong M; Buisson M; Grappin M; Quantin C; Portier H; Chavanet P; Piroth L
    HIV Clin Trials; 2003; 4(6):400-10. PubMed ID: 14628283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-related liver disease: ARV drugs, coinfection, and other risk factors.
    Puoti M; Nasta P; Gatti F; Matti A; Prestini K; Biasi L; Carosi G
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(1):30-42. PubMed ID: 19211929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic hepatitis C in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
    Halota W; Pawłowska M
    Przegl Epidemiol; 2002; 56 Suppl 5():41-5. PubMed ID: 15553071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Treatment of Mitochondrial Toxicity in an HIV-Positive Patient After Liver Transplantation.
    Kim IK; Gaultier C; Steggerda J; Pan SH; Klein AS; Annamalai A; Tran T; Nissen NN
    Transplant Proc; 2015 Nov; 47(9):2771-4. PubMed ID: 26680091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.